EDINBURGH, Scotland, Oct. 22,
2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC
BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage
biotechnology company developing platform allogeneic gamma-delta T
cell therapies for cancer and other indications, today announced it
has entered into a research planning collaboration with Dr.
Carlos Maluquer de Motes for the development of a treatment for
Monkeypox.
Dr. Carlos Maluquer de Motes is Reader and Principal
Investigator at the University of Surrey,
United Kingdom and works closely with The Pirbright
Institute, a leading center of excellence in research of viral
diseases that spread from animals to humans. After receiving his
PhD in Virology from the University of
Barcelona, he joined the laboratory of Claude Krummenacher and Gary Cohen at the University of Pennsylvania to study herpesvirus
immune evasion. In 2009, he joined the laboratory of Geoffrey Smith at Imperial College London and
subsequently the University of
Cambridge to study vaccinia virus modulation of innate
immunity and cell death.
"We've seen the ramifications of a global pandemic and the havoc
it can inflict," said Bryan Kobel,
CEO of TC BioPharm. "There is significant data stating that a
successful immune response to viral infection is heavily reliant on
the presence of gamma delta t-cells, both in the preventative
sense and in the successful outcomes of patients with viral
infection. We believe that our lead therapeuticTCB008 could play an
important role in treating this virus as well as other infectious
diseases, providing a bolstered level of gamma delta t-cells
to generate a more effective immune response in patients who are
facing severe viral infection TCB also intends to explore the use
of TCB008 in a prophylactic setting for infectious diseases with
the intent to provide TCB008 in a supportive or adjunct use for
patients at high risk of infection to various diseases when
immune-compromised or suppressed in hospital settings or by age
where the immune system and gamma delta t-cell population has
weakened. After meeting with a number of experts, our team and I
were impressed with Carlos' approach to this potential research
plan and his prior stellar work in infectious disease research. We
look forward to working with Dr. Maluquer de Motes and playing an
important role in addressing this underserved need."
Mpox is an infectious viral disease that can occur in humans and
other animals. Symptoms include a rash that forms blisters, fever,
and swollen lymph nodes. Since the beginning of Mpox monitoring in
2022, there have been more than 100,000 confirmed cases including
over 200 deaths. Cases have been reported by more than 120
countries globally according to the World Health Organization
(WHO).
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this Current Report on Form 8-K
that do not relate to matters of historical fact should be
considered forward-looking statements, including without limitation
statements regarding the Company's intent or ability to affect any
budget savings or execute on any M&A or capital raising
strategy. These statements are based on management's current
assumptions and are neither promises nor guarantees but involve
known and unknown risks, uncertainties and other important factors
that may cause the Company's actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. For other important factors that could
cause actual results to differ materially from the forward-looking
statements in this Current Report on Form 8-K, please see the risks
and uncertainties identified under the heading "Risk Factors" in
our Annual Report on Form 10-K for the year ended December 31, 2023, and our other reports filed
with the SEC, all of which is available on the Company's Investor
Relations website at www.tcbiopharm.com and on the SEC
website at www.sec.gov. All forward-looking statements reflect
the Company's beliefs and assumptions only as of the date of this
Current Report on Form 8-K. The Company undertakes no obligation to
update forward-looking statements to reflect future events or
circumstances.
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company
focused on discovering, developing, and commercializing gamma-delta
T-cell therapies for cancer treatment with human efficacy data in
acute myeloid leukemia. Gamma-delta T cells are naturally occurring
immune cells that embody properties of both the innate and adaptive
immune systems and can intrinsically differentiate between healthy
and diseased tissue.
TC BioPharm is the leader in developing gamma-delta T cell
therapies, and the first company to conduct phase II/pivotal
clinical studies in oncology. The Company is conducting two
investigator-initiated clinical trials for its unmodified
gamma-delta T cell product line - Phase 2b/3 pivotal trial in treating acute myeloid
leukemia using the Company's proprietary allogeneic CryoTC
technology to provide frozen product to clinics worldwide.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/tcbp-enters-research-planning-collaboration-with-dr-carlos-maluquer-de-motes-for-mpox-therapeutic-302282990.html
SOURCE TC BioPharm
